Displaying results 1 - 12 of 18
Liver Cancer Explained • Liver cancer is the third leading cause of cancer-related deaths worldwide and the primary cause of death for patients with cirrhosis. Most of liver cancers are hepatocellular carcinomas, however some patients develop intrahepatic cholangiocarcinomas (ICC) or rare tumours in non-cirrhotic livers. Chronic liver diseases, alcohol consumption, obesity and diabetes, non-alcoholic fatty liver disease (NAFLD), exposure to aflatoxins, as well as chronic infection with HBV or HCV are considered risk factors. The burden of adult liver cancers and HCC is still increasing and various public health strategies have been developed for the prevention and control of this trend which will likely remain a major public health problem worldwide in the upcoming decades. Discover the infographic below illustrating key information for a better understanding of liver cancer. Liver Cancer Explained Infographic
Metabolism, Alcohol & Toxicity
Reducing the burden of alcohol-related liver disease (ARLD) • ARLD is responsible for nearly 40,000 deaths in Europe every year and alcohol consumption is directly correlated with liver disease mortality in most EU countries. It is largely a ‘silent’ illness, in 75% of cases, it is not identified until the patient is in the emergency room, with heavy drinkers at exponentially higher risk of cirrhosis. To address this growing problem, EASL is calling on all European countries to limit alcohol consumption and increase disease detection by implementing five key recommendations. In doing so, we can all reduce the personal and economic burden of ARLD.
Metabolism, Alcohol & Toxicity
Obesity and non-alcoholic fatty liver disease (NAFLD) • NAFLD is one of the most common causes of cirrhosis, liver transplant and liver cancer worldwide. Its prevalence is rising, in line with that of risk factors such as obesity and unhealthy lifestyles. There are no licenced medications for NAFLD, but it can be avoided and successfully treated by making lifestyle modifications including healthy eating and increased exercise. To mitigate the societal burden of NAFLD, EASL is calling on all European countries to adopt key policy changes which discourage consumption while improving health education and awareness. We can all do our part to reduce the risk of NAFLD.
Eliminating hepatitis C • Despite the ability of new direct-acting antiviral therapies to cure hepatitis C in almost all treated patients, HCV is still responsible for 400,000 deaths worldwide every year. Not only do patients face a number of barriers to treatment, but infection is largely asymptomatic until its later stages, leading to cirrhosis and liver cancer. To tackle the challenge of HCV, EASL is calling on all European countries to implement the WHO Global Health Sector Strategy on Viral Hepatitis action plan. EASL and the WHO believe that HCV can be eliminated as a public health threat by 2030, but we need to work together and take action now.
EASL Patient Synergies Roundtable Discussion: Improving the Lives of Liver Cancer Patients • Description For Digital Liver Cancer Summit 2021, 5-6 February, and on the occasion of World Cancer Day, 4 February, EASL held a discussion aiming to identify the needs of liver cancer patients and their families, and the best ways to accompany them. The Roundtable Discussion was an open interaction between scientists, patient representatives, and nurses on three topics identified by the EASL-affiliated patient associations of EASL Patient Synergies. Programme and learning objectives Session 1: Early diagnosis and risk factors of liver cancer Understand the importance of information, early diagnosis and prevention measurements, such as vaccination Learn more about the key recent accomplishments in the early detection of HCC Apprehend the challenges encountered with early detection of HCC Session 2: COVID-19 challenges and liver cancer care What improvements in patient support and promotion of connectedness have taken place during COVID for people living with a liver cancer diagnosis and how can we continue to provide these benefits moving forward? What kind of impact will this situation have on cancer patients? Session 3: The inequality of the burden of cancer in different European countries Present the inequality of cancer burden in different European countries, linking this to their causes (prevention and survival) Understand the differences in cancer survival (diagnosis and access to treatment) Faculty Maria Reig, BCLC group, Liver Unit, Hospital Clínic of Barcelona, University of Barcelona, IDIBAPS, CIBERehd, Spain Pierre Nahon, Paris-Seine-Saint-Denis Hospital, France Isabelle Soerjomataram, International Agency for Research on Cancer (IARC), France Session 1: Early diagnosis and risk factors of liver cancer